Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Counting the Votes: Democrats Consider Their Public Options On Health Reform and Reconciliation

This article was originally published in RPM Report

Executive Summary

Democrats always feared having the health care reform debate carrying over past August. Now it’s October. Media coverage of chaotic town hall meetings, intra-party disputes, and a united Republican opposition show how prescient the Democrats were to worry about debate after the summer holidays. Democrats are now starting to consider how they’ll vote on a fi nal bill. Here’s what it could look like if the legislation goes through the Congressional shortcut of budget reconciliation and includes a public plan.

You may also be interested in...



Health Reform in the Balance: What It Means for Biopharma

The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach.

Health Care Reform and Business Development: 10 Reasons it Matters

The drama of the health care reform debate is undeniable, but that doesn’t mean it’s easy to see how it will change the business of drug development. But it will, and we’ll give you 10 reasons why.

Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?

Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel